AstraZeneca (AZN) Lower, Loses Certain CRESTOR Patent Decision
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Down)Join SI Premium – FREE
AstraZeneca plc (NYSE: AZN) is ticking lower following headlines that it lost a ruling over 2018 and 2022 CRESTOR patents. Shares are down 0.7 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- AstraZeneca (AZN) shares jump on much stronger Q1 top and bottom line
- Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study
Create E-mail Alert Related Categories
FDA, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
